Guess what I got to bring home with me today... the GRN163L clinical trial protocol. This is a single agent Phase I does escolation study with a weekly 2 hour infusion (and clinical trial related blood work, etc. etc. etc.) Although there is a relatively short history with GRN163L my impression after spending a considerable amount of time with the research nurse and oncologist was the side effects appear pretty tame and the potential efficacy being significant (at least for the CLL Trial). A single patient (out of about a dozen) experienced poor blood clotting ability (PT/INR).
There is no clinical MM efficacy to relay as the study has not yet recruited a single patient.